Advances in sustained-release drug delivery could improve efficiency and consistency in drug release, manifesting real-life advantages for patients in the form of enhanced accessibility and compliance. Reducing API particle size down to the uniquely small nano-size range could facilitate smaller implants with increased drug load.
Demand for HPAPIs is rising as more companies opt for the benefits presented by lower dosage forms. Accessing specialized facilities with HPAPI handling capabilities is crucial to ensure the safe development and manufacturing of these drug substances.
As patients take an increasingly active role in their own health and become more empowered, it is essential to promote better adherence, improve medical benefits, and bolster market perception. Explore the evolving technologies enabling this shift toward improved quality of life and the potential of nanotechnology to aid this transition.
Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor. It is difficult to treat and has a high risk of recurrence after surgery, placing efficacious treatments in high demand. Discover new possibilities for increased dosing capabilities and diffusion across the brain parenchyma offered by nanoformed APIs.
By adopting transformative technologies that reduce waste and emissions, the pharma industry can help to forge a greener, healthier future for all. Discover how nanoparticle engineering technology can both empower sustainability goals and lead to better patient outcomes.
Nanoform’s facility utilizes its award-winning Controlled Expansion of Supercritical Solutions (CESS®) technology for the manufacture of API nanoparticles to GMP standards, and all GMP activities are regularly inspected by the national competent authority, the Finnish Medicines Agency.
